Redeye comments on Active Biotech's fourth quarter report. The US clinical study in myelofibrosis has has recommenced as of February, and the European study is expected to reopen in Q1. After the conclusion of the rights issue, the company is funded over 2026-2027. We believe a potential laquinimod deal could move the share.
LÄS MER
